CN108309969A - 鸢尾黄素在治疗鸡坏死性肠炎中的医用用途 - Google Patents

鸢尾黄素在治疗鸡坏死性肠炎中的医用用途 Download PDF

Info

Publication number
CN108309969A
CN108309969A CN201810470739.7A CN201810470739A CN108309969A CN 108309969 A CN108309969 A CN 108309969A CN 201810470739 A CN201810470739 A CN 201810470739A CN 108309969 A CN108309969 A CN 108309969A
Authority
CN
China
Prior art keywords
tectorigenin
chicken
necrotizing enterocolitis
medical application
perfringens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201810470739.7A
Other languages
English (en)
Other versions
CN108309969B (zh
Inventor
邓旭明
刘水
王建锋
张建
王婷婷
周永林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong Guangyuan Pharmaceutical Technology Co ltd
Shandong Jinzhuji Pharmaceuticals Co ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201810470739.7A priority Critical patent/CN108309969B/zh
Publication of CN108309969A publication Critical patent/CN108309969A/zh
Priority to PCT/CN2019/086738 priority patent/WO2019218986A1/zh
Priority to US16/963,208 priority patent/US11491135B2/en
Application granted granted Critical
Publication of CN108309969B publication Critical patent/CN108309969B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Fodder In General (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Feed For Specific Animals (AREA)

Abstract

本发明公开了鸢尾黄素在治疗鸡坏死性肠炎中的医用用途,提供了鸢尾黄素的一种新医用用途,用于治疗鸡坏死性肠炎,可显著降低坏死性肠炎鸡只肠道的病理变化程度,对产气荚膜梭菌所致的鸡坏死性肠炎具有良好的治疗效果。

Description

鸢尾黄素在治疗鸡坏死性肠炎中的医用用途
技术领域
本发明公开了鸢尾黄素在治疗鸡坏死性肠炎中的医用用途,涉及鸢尾黄素在制备治疗鸡坏死性肠炎药物中的应用,属于医药技术领域。
背景技术
产气荚膜梭菌是一种厌氧性革兰氏阳性芽孢杆菌,广泛存在于自然界的土壤、水体、食物、人畜粪便、家畜饲料及动物肠道中,是人和动物的正常肠道菌群,属条件致病菌。目前根据其分泌的外毒素不同,将其分为A-E 共个5血清型,家禽主要感染A型及C型产气荚膜梭菌,尤以A型为主。产气荚膜梭菌感染家禽后,主要引起坏死性肠炎,其症状表现为鸡只精神委靡、羽毛松乱、食欲减少或废绝,排血便,生产性能严重下降。病变主要集中在小肠部位,表现为肠壁变薄,有局灶性或成片的肠粘膜坏死脱落。据有关研究统计,全球家禽行业因坏死性肠炎造成的经济损失高达数十亿美元,严重危害了家禽养殖业的发展。
产气荚膜梭菌在肠道内的粘附定植主要是通过其四型菌毛(Type IV pili,TFP)介导的。TFP是一种存在于细菌细胞膜上的一种运动器官,TFP使得产气荚膜梭菌具有在其自然生境和软硬琼脂等半固体的介质表面运动的能力,这种特殊的运动方式被称作滑动运动(Gliding motility)。据研究表明,包括产气荚膜梭菌在肠道的粘附定植、滑动运动、生物被膜的形成等细菌功能都与TFP具有一定的联系。通过抑制产气荚膜梭菌TFP的功能,能够干扰细菌在肠道内的粘附定植,从而达到抗产气荚膜梭菌感染的目的。
通过在饲料中添加抗生素是预防并治疗家禽感染坏死性肠炎的主要手段,然而,由于抗生素大量使用所致的细菌耐药性问题及抗生素残留问题对公众健康造成了严重威胁,因此,开发安全有效的抗生素替代物正日益成为研究的热点。天然化合物具有毒性较低、来源丰富、安全范围广等优点,是筛选抗生素替代物的重要资源。
鸢尾黄素是一种天然存在的异黄酮类化合物,主要存在于鸢尾科鸢尾属和射干属植物的根、茎中。目前的研究表明,鸢尾黄素具抗炎、抗癌、保肝、抗氧化及雌激素样作用等生物学活性。近年来,大量的文献对鸢尾黄素的药理活性进行了报道,但是,截至目前国内外尚无鸢尾黄素用于治疗产气荚膜梭菌所致鸡坏死性肠炎的相关研究。
发明内容
本发明提供了鸢尾黄素在治疗鸡坏死性肠炎中的医用用途,对产气荚膜梭菌所致的鸡坏死性肠炎具有良好的治疗效果。
本发明所述的鸢尾黄素的分子结构如下所示:
分子式为:C16H12O6;分子量: 300.263。
本发明通过产气荚膜梭菌滑动运动抑制试验、生物被膜形成抑制试验以及雏鸡坏死性肠炎模型试验证鸢尾黄素对产气荚膜梭菌感染所致的鸡坏死性肠炎具有保护作用:
一、滑动运动抑制试验:
产气荚膜梭菌标准株ATCC13124于液体BHI培养基37 ℃厌氧培养12 h,之后取300 μl该培养物继续培养于液体BHI中,37 ℃厌氧培养5 h。取1 ml培养物,10000 g离心弃上清,菌体重悬于500 μl BHI液体培养基中,使之二倍浓缩。之后取5 μl浓缩的菌液分别滴加于预先制备并于37 ℃烘箱干燥1 h的含8 μg/ml、32 μg/ml鸢尾黄素的0.7% BHIA的平板上,37 ℃厌氧培养48 h,采集图像(参见图1)。结果表明,8 μg/ml及32 μg/ml鸢尾黄素均能显著抑制产气荚膜梭菌在BHIA上的滑动运动,且32 μg/ml鸢尾黄素作用效果更为明显。
二、生物被膜形成抑制试验
产气荚膜梭菌于液体BHI中37℃厌氧培养12h,离心弃上清,用灭菌PBS洗涤一次,之后用TSB液体培养基重悬并调整至OD600nm=0.1,取400μl调整后的细菌培养物,加至24孔板中,之后与细菌培养物内分别加入不同浓度的鸢尾黄素,使得24孔板内鸢尾黄素的终浓度分别为4 μg/ml、8 μg/ml、/16μg/ml及32μg/ml,另设立加入0.4μl过滤灭菌的DMSO(不加入鸢尾黄素)的阳性对照组以及400 μl液体TSB培养基的阴性对照组,24孔板置于30 ℃厌氧培养5d。之后吸弃上清,灭菌PBS洗两次,室温干燥30 min,加入过滤灭菌的1%结晶紫400μl,室温孵育30min,弃结晶紫,再次用灭菌PBS洗两次。向每孔中加入33%乙酸溶解结晶紫,吹打混匀后取300 μl分别加入96孔板的3个独立孔中,每孔100μl,于酶标仪570 nm测定吸光值,根据结晶紫吸光值计算生物被膜形成率。结果表明,鸢尾黄素能够有效抑制产气荚膜梭菌生物被膜的形成(参见图2)。
三、雏鸡坏死性肠炎模型试验的治疗学研究
1、雏鸡坏死性肠炎模型
取17日龄的雄性爱拔益加(Arbor Acre)肉仔鸡经口给予0.5 ml(1×109CFUs)重悬于灭菌PBS的产气荚膜梭菌ATCC13124培养物,次日(18日龄)再次给予相同菌量的菌液以攻菌,建立雏鸡坏死性肠炎模型,健康组鸡只经口给予0.5 ml灭菌PBS作为对照。
2、肠道病变评分试验
雏鸡经口攻菌感染前4 h(17日龄)按鸡只体重经口给予25 mg/kg的鸢尾黄素(溶解于灭菌PBS),每12h给药一次。另设立不给药治疗的阳性对照组及不攻菌感染的健康对照组,阳性对照组与健康对照组鸡只同样称重并按体重经口给予相应体积的灭菌PBS。上述三组每组10只鸡,治疗组共给药治疗5天(治疗至21日龄)。21日龄颈椎脱臼处死全部鸡只,剖检,取十二指肠至空肠,肉眼观察肠道病理变化,根据肠道损伤程度进行肠道损伤评分(参见图3)。肠道损伤评分采用0-6分制:0分(没有明显损伤)、1分(肠壁变薄、变脆)、2分(出现1-5个坏死灶)、3分(出现6-15个坏死灶)、4分(出现16个或16个以上坏死灶)、5分(出现2-3 cm长的片状坏死)、6分(出现大片的弥漫性坏死)。另将上述小肠采集病料,HE染色制作病理切片,镜下观察病理组织学变化(参见图4)。
攻菌期间每日对全部肉鸡称重,计算平均体重及日增重,以考察鸢尾黄素治疗后对患坏死性肠炎肉鸡日增重的影响(参见图5)。
肠道病变评分结果表明,经鸢尾黄素治疗后,显著降低了坏死性肠炎鸡只肠道的病理变化程度。病理组织学观察结果表明,健康组肉鸡小肠肠绒毛结构完整,无出血及炎性渗出;对照组肉鸡小肠绒毛坏死溶解,结构不完整,伴有大量出血;经鸢尾黄素治疗后,上述病理组织学损伤明显缓解。日增重结果表明,治疗组肉鸡日增重与健康组肉鸡相近,显著高于感染组肉鸡。
综合以上结果,说明鸢尾黄素对产气荚膜梭菌所致的鸡坏死性肠炎具有良好的保护作用。
本发明的积极效果在于:提供了鸢尾黄素的一种新医用用途,用于治疗鸡坏死性肠炎,可显著降低坏死性肠炎鸡只肠道的病理变化程度,对产气荚膜梭菌所致的鸡坏死性肠炎具有良好的治疗效果。
附图说明
图1为鸢尾黄素均能显著抑制产气荚膜梭菌在BHIA上的滑动运动图片;
图2为鸢尾黄素能够有效抑制产气荚膜梭菌生物被膜的形成图;
图3为根据肠道损伤程度进行肠道损伤评分图;
图4为镜下观察病理组织学变化照片;
图5为鸢尾黄素治疗后对患坏死性肠炎肉鸡日增重的影响图。
具体实施方式
实施例1
鸢尾黄素在制备治疗鸡坏死性肠炎药物中的应用,以鸢尾黄素为活性制成药学上可接受任何剂型。
实施例2
鸢尾黄素所述的治疗鸡坏死性肠炎指由细菌引起的坏死性肠炎。
实施例3
鸢尾黄素所述的治疗鸡坏死性肠炎是指由产气荚膜梭菌引起的坏死性肠炎。

Claims (4)

1.鸢尾黄素在制备治疗鸡坏死性肠炎药物中的医用用途。
2.权利要求1所述鸢尾黄素在制备治疗鸡坏死性肠炎药物中的医用用途中涉及的鸡坏死性肠炎指由细菌引起的坏死性肠炎。
3.权利要求1所述鸢尾黄素在制备治疗鸡坏死性肠炎药物中的医用用途中涉及的鸡坏死性肠炎指由产气荚膜梭菌引起的坏死性肠炎。
4.以鸢尾黄素为活性成分制成药学上可接受任何剂型。
CN201810470739.7A 2018-05-17 2018-05-17 鸢尾黄素在治疗鸡坏死性肠炎中的医用用途 Active CN108309969B (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201810470739.7A CN108309969B (zh) 2018-05-17 2018-05-17 鸢尾黄素在治疗鸡坏死性肠炎中的医用用途
PCT/CN2019/086738 WO2019218986A1 (zh) 2018-05-17 2019-05-14 鸢尾黄素在治疗鸡坏死性肠炎中的医用用途
US16/963,208 US11491135B2 (en) 2018-05-17 2019-05-14 Medical use of tectorigenin in treatment of chicken necrotic enteritis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810470739.7A CN108309969B (zh) 2018-05-17 2018-05-17 鸢尾黄素在治疗鸡坏死性肠炎中的医用用途

Publications (2)

Publication Number Publication Date
CN108309969A true CN108309969A (zh) 2018-07-24
CN108309969B CN108309969B (zh) 2020-02-21

Family

ID=62896357

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810470739.7A Active CN108309969B (zh) 2018-05-17 2018-05-17 鸢尾黄素在治疗鸡坏死性肠炎中的医用用途

Country Status (3)

Country Link
US (1) US11491135B2 (zh)
CN (1) CN108309969B (zh)
WO (1) WO2019218986A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019218986A1 (zh) * 2018-05-17 2019-11-21 山东广元药业科技有限公司 鸢尾黄素在治疗鸡坏死性肠炎中的医用用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006206557A (ja) * 2005-01-31 2006-08-10 Ota Isan:Kk アルコール誘発性疾病予防、治療剤及びその製造方法
CN101185707A (zh) * 2006-11-23 2008-05-28 河北智同医药控股集团有限公司 一种抗炎抗病毒的药物组合物,其制备方法和应用
WO2010009735A9 (en) * 2008-07-23 2010-07-29 Dako Denmark A/S Combinatorial analysis and repair
WO2014099134A1 (en) * 2012-12-18 2014-06-26 Mjn U.S. Holdings Llc Milk-based nutritional compositions containing lactoferrin and uses thereof
CN108261483A (zh) * 2018-04-16 2018-07-10 山东金铸基药业有限公司 一种用于治疗鸡坏死性肠炎的川射干口服液及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100544716C (zh) 2006-12-11 2009-09-30 中国人民解放军第二○八医院 鸢尾苷元制备工艺及其制备抗动脉粥样硬化药物中的应用
CN108309969B (zh) 2018-05-17 2020-02-21 山东广元药业科技有限公司 鸢尾黄素在治疗鸡坏死性肠炎中的医用用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006206557A (ja) * 2005-01-31 2006-08-10 Ota Isan:Kk アルコール誘発性疾病予防、治療剤及びその製造方法
CN101185707A (zh) * 2006-11-23 2008-05-28 河北智同医药控股集团有限公司 一种抗炎抗病毒的药物组合物,其制备方法和应用
WO2010009735A9 (en) * 2008-07-23 2010-07-29 Dako Denmark A/S Combinatorial analysis and repair
WO2014099134A1 (en) * 2012-12-18 2014-06-26 Mjn U.S. Holdings Llc Milk-based nutritional compositions containing lactoferrin and uses thereof
CN108261483A (zh) * 2018-04-16 2018-07-10 山东金铸基药业有限公司 一种用于治疗鸡坏死性肠炎的川射干口服液及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PRIYANKA PAL ET AL: "APOPTIC ACTIVITY OF CHICKEN ANEMIA VIRUS VP3 GENE CLONED IN REPLICASE BASED EUKARYOTIC VECTOR", 《THE JOURNAL OF MICROBIOLOGY,BIOTECHONOLOGY AND FOOD SCIENCES》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019218986A1 (zh) * 2018-05-17 2019-11-21 山东广元药业科技有限公司 鸢尾黄素在治疗鸡坏死性肠炎中的医用用途
US11491135B2 (en) 2018-05-17 2022-11-08 Shandong Guangyuan Pharmaceutical Sci. & Tech.Co., Ltd Medical use of tectorigenin in treatment of chicken necrotic enteritis

Also Published As

Publication number Publication date
WO2019218986A1 (zh) 2019-11-21
US20210121439A1 (en) 2021-04-29
CN108309969B (zh) 2020-02-21
US11491135B2 (en) 2022-11-08

Similar Documents

Publication Publication Date Title
Wang et al. Bacteriostatic effect of quercetin as an antibiotic alternative in vivo and its antibacterial mechanism in vitro
PT986314E (pt) Bactéria láctica probiótica para tratar infecções bacterianas associadas à sids
WO2007058027A1 (ja) バチルス・チューリンゲンシスを含む有害菌の防除剤
Paraud et al. Evaluation of oral tilmicosin efficacy against severe cryptosporidiosis in neonatal kids under field conditions
CN108836956A (zh) 甘草查耳酮a在制备治疗鸡坏死性肠炎药物中的用途
WO2013112582A1 (en) Sandalwood oil and its uses related to clostridium infections
CN105287790A (zh) 一种鸡矢藤提取物及其应用
CN102920771B (zh) 一种用于治疗家禽球虫病的药物
Mahmoud et al. Effect of Chinese propolis supplementation on Ross broiler chicks: microbial population in fecal matter and litter
CN108309969A (zh) 鸢尾黄素在治疗鸡坏死性肠炎中的医用用途
RU2197237C2 (ru) Способ лечения заболеваний животных, вызванных бактериями (варианты), и способ изготовления лекарственного средства
Kumar et al. Evaluation of anti-ulcerogenic properties from the root of Flemingia strobilifera
US20210121538A1 (en) Interactional Biosystem
CN110464791A (zh) 一种丝兰属植物在预防鸡坏死性肠炎的应用
Olusola et al. The potential of different extraction methods of soursop (Annona muricata Linn) leaves as antimicrobial agents for aquatic animals
CN106924229B (zh) 根皮素在制备治疗鸡坏死性肠炎药物中的应用
CN103721240B (zh) 一种治疗畜禽消化道细菌性感染的复方制剂及其制备方法
CN108853081A (zh) 穗花杉双黄酮在治疗鸡坏死性肠炎中的医用用途
CN107260796A (zh) 百里香复方植物精油在防治鸡坏死性肠炎中的应用
CN103027997A (zh) 一种用于防治鲟因感染嗜水气单胞菌发病的中草药复方
Giannenas et al. Effect of a multi-strains yeast fractions product plus anticoccidial drug on performance, anticoccidial index, intestinal health, and bone mineralization of broiler chickens infected with Eimeria spp
CN101129379A (zh) 抗球虫药物组合物及其制备方法
CN104688726A (zh) 异黄酮类化合物在制备抗微小隐孢子虫药物中的应用
JP5970483B2 (ja) 胞子欠損B.テクサスポルス(B.texasporus)細胞、及び効率的且つ費用対効果の高い不活性化のための方法、及びその使用
CN107375413A (zh) 肉豆蔻精油和罗勒精油在防治鸡坏死性肠炎中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20190522

Address after: 262400 Nine-level Village South of Zhuliu Street, Changle County, Weifang City, Shandong Province

Applicant after: SHANDONG GUANGYUAN PHARMACEUTICAL TECHNOLOGY Co.,Ltd.

Applicant after: SHANDONG JINZHUJI PHARMACEUTICALS Co.,Ltd.

Address before: 130012 College of Animal Medicine, 5333 Xi'an Road, Changchun City, Jilin Province

Applicant before: Deng Xuming

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Medical use of iridin in the treatment of chicken necrotizing enteritis

Effective date of registration: 20230103

Granted publication date: 20200221

Pledgee: Laiwu branch of China Postal Savings Bank Co.,Ltd.

Pledgor: SHANDONG JINZHUJI PHARMACEUTICALS Co.,Ltd.

Registration number: Y2023980030083

PE01 Entry into force of the registration of the contract for pledge of patent right